Hungarian drugmaker Richter Gedeon has reported sales of $222 million for 1995, a rise of $20 million, or 9.9%, on the previous year, according to MTI Econews. Exports were worth $149.8 million, including exports of $60.9 million to the Commonwealth of Independent States. Econews notes that these exports to the CIS were very impressive, especially given that they resulted from deals struck with private companies rather than with the state.
Richter Gedeon's turnover on the domestic market was worth some 8.93 billion forint ($61.8 million), a rise of 26.4% on 1994. Its gross profits in 1995 totalled 7.72 billion forint, up 3 billion forint on 1994 and 600 million higher than the management had forecast last November.
The company's shares closed up 500 points on the Budapest Stock Exchange on February 8, to reach a 12-month high of 4,700 forint per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze